PSMA-targeted docetaxel (BIND-014) - Pfizer
BIND Therapeutics: Annual Report 2014 (BIND Therapeutics) - Mar 13, 2015 - “BIND-014: Phase 2 Data in NSCLC”; “Tumor Response: all patients (BIND-014 Q3W schedule at 60 mg/m2, n=40” 
P2 data • Non Small Cell Lung Cancer • Oncology
http://files.shareholder.com/downloads/AMDA-245CHD/4094828494x0xS1193125-15-87467/1385228/filing.pdf
 
Mar 13, 2015
 
.
 
aff224a7-81af-487f-bc01-94e5486bd22f.jpg